m 102.4

Drug Profile

m 102.4

Alternative Names: Antiviral monoclonal antibody - Profectus BioSciences; Hendra virus monoclonal antibody - Profectus BioSciences; m 102; m102.4 mAb; Nipah virus monoclonal antibody - Profectus BioSciences

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator National Cancer Institute (USA); Profectus Biosciences; Uniformed Services University of the Health Sciences
  • Developer Profectus Biosciences
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Eph family receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Viral infections
  • No development reported Nipah virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Nipah-virus-infections in USA
  • 14 Apr 2015 Phase-I clinical trials in Viral infections (In volunteers) in Australia (IV) (ACTRN12615000395538)
  • 13 Dec 2011 Preclinical trials in Nipah virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top